MedTrace Logo

Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients

NCT02392312 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 950

Last updated 2024-10-21

No results posted yet for this study

Summary

A multicenter, prospective, observational study to evaluate the safety and efficacy of individual batches of ATG-F in kidney transplant recipients.

Conditions

  • Kidney Transplant Recipients

Interventions

DRUG

ATF-Fresenius S

intravenous

Sponsors & Collaborators

  • Astellas Pharma China, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Astellas Pharma China, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-21
Primary Completion
2018-03-16
Completion
2018-03-16

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02392312 on ClinicalTrials.gov